专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20180080080A1 GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS 审中-公开
公开(公告)号：US20180080080A1
公开(公告)日：2018-03-22
申请号：US15662079
申请日：2017-07-27
申请人： Genentech, Inc.
发明人： MICHAEL TOWNSEND , ALVERNIA FRANCESCA SETIADI , TRACY STATON
IPC分类号： C12Q1/68 , C07K16/24 , G01N33/564
CPC分类号： C12Q1/6883 , A61K2039/505 , C07K16/244 , C07K2317/76 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/564 , G01N2333/47 , G01N2333/522 , G01N2333/535 , G01N2333/5412 , G01N2333/5421 , G01N2333/8146 , G01N2800/285 , G01N2800/50 , G01N2800/52
摘要： The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.

62. 发明申请

US20170153250A1 DIAGNOSIS AND TREATMENT OF KAWASAKI DISEASE 审中-公开
公开(公告)号：US20170153250A1
公开(公告)日：2017-06-01
申请号：US15327280
申请日：2015-07-23
申请人： Academia Sinica
发明人： Yuan-Tsong Chen , Jer-Yuarn Wu , Tai-Ming Ko , Ho-Chang Kuo , Jeng-Sheng Chang
IPC分类号： G01N33/68 , A61K31/56 , A61K39/395
CPC分类号： G01N33/6893 , A61K31/56 , A61K39/395 , A61K2039/505 , C07K16/00 , G01N33/6863 , G01N33/6869 , G01N2333/522 , G01N2333/54 , G01N2333/5418 , G01N2333/7056 , G01N2333/70578 , G01N2800/328
摘要： Described is a method of diagnosing, treating, or monitoring a treatment for Kawasaki disease in a subject. The method includes detecting the level of a biomarker in a sample obtained from the subject, the biomarker being IL-7F, sCD40L, MPIF-1, E-selectin, IP-10, or IL-33. The level is compared to a cut-off level. Also described is a kit for carrying out the method.

63. 发明申请

US20170059581A1 METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILES 审中-公开
标题翻译：使用细胞因子轮廓诊断和预防炎症性皮肤病的方法
公开(公告)号：US20170059581A1
公开(公告)日：2017-03-02
申请号：US15258050
申请日：2016-09-07
申请人： THE JOHNS HOPKINS UNIVERSITY , Oklahoma Medical Research Foundation
发明人： Xuhang Li , Philip J. Alex , Michael B. Centola , Nicholas Knowlton
IPC分类号： G01N33/68
CPC分类号： G01N33/6863 , C07K14/52 , G01N33/6866 , G01N33/6869 , G01N2333/521 , G01N2333/522 , G01N2333/535 , G01N2333/5403 , G01N2333/5406 , G01N2333/5409 , G01N2333/5412 , G01N2333/5421 , G01N2333/5428 , G01N2333/5434 , G01N2333/545 , G01N2333/55 , G01N2333/57 , G01N2800/065 , G01N2800/60
摘要： The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohn's Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10.
摘要翻译：本发明涉及炎症性肠病领域。更具体地，本发明涉及细胞因子用于检测，诊断和评估炎症性肠病的用途。在一个实施方案中，用于诊断患者中的克罗恩病（CD）的方法包括以下步骤：（a）从患者收集样品; （b）测量从患者收集的样品中至少一种细胞因子的水平; 和（c）将至少一种细胞因子的水平与预定的细胞因子水平进行比较，其中患者样品中的细胞因子水平与预定的细胞因子水平之间的相关性指示患者具有CD。在一个具体的实施方案中，所述至少一种细胞因子包括干扰素（IFN）-γ，白介素（IL）-1β，IL-6，IL-8，IL-12，IL-17和CXCL10。

64. 发明授权

US09523687B2 Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS 有权
标题翻译： CXCL 10 / IP-10形式的水平和可溶性CD26 / DPPIV活性作为HIV / SIV相关粘膜炎症和艾滋病进展的早期预测生物标志物
公开(公告)号：US09523687B2
公开(公告)日：2016-12-20
申请号：US14193835
申请日：2014-02-28
申请人： INSTITUT PASTEUR
发明人： Michaela Müller-Trutwin , Mickaël J. Y. Ploquin , Matthew Albert , Yoann Madec , Cécile Goujard , Laurence Meyer
IPC分类号： G01N33/00 , G01N33/569
CPC分类号： G01N33/56988 , G01N2333/522 , G01N2333/70596 , G01N2800/50 , G01N2800/52
摘要： The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.
摘要翻译：本发明提供了用于鉴定能够控制HIV进展的患者的方法，以及鉴定与HIV进展控制相关的IP-10的拮抗剂形式及其用于改善HIV患者的免疫应答的方法。

65. 发明申请

US20160209427A1 BIOMARKERS FOR LOWER URINARY TRACT SYMPTOMS (LUTS) 审中-公开
公开(公告)号：US20160209427A1
公开(公告)日：2016-07-21
申请号：US15085587
申请日：2016-03-30
申请人： The Regents of The University of Michigan
发明人： Mitchell B. Berger , Andrew Johnston
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/48 , G01N2333/485 , G01N2333/522 , G01N2333/523 , G01N2333/5403 , G01N2333/5412 , G01N2333/5428 , G01N2333/5434 , G01N2333/70575 , G01N2800/341 , G01N2800/50 , G01N2800/52
摘要： Provided herein are compositions and methods for the characterization of a subject's predisposition to developing lower urinary tract symptoms (LUTS). In particular, biomarkers are provided that identify the likelihood that a subject with develop LUTS concomitant with pelvic organ prolapse (POP), and/or the likelihood that LUTS will persist after surgical repair of POPS.

66. 发明授权

US09309312B2 Immunoassay method for human CXCL1 protein 有权
标题翻译：人类CXCL1蛋白免疫测定法
公开(公告)号：US09309312B2
公开(公告)日：2016-04-12
申请号：US13126877
申请日：2009-10-29
申请人： Satoko Kanamori , Giman Jung , Yoshinori Tanaka , Aiko Takayama
发明人： Satoko Kanamori , Giman Jung , Yoshinori Tanaka , Aiko Takayama
IPC分类号： C07K16/24 , G01N33/68 , G01N33/543 , G01N33/563 , A61K39/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N33/543 , G01N33/6857 , G01N33/6863 , G01N2333/522
摘要： An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein: each of the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognizes any one of sequence regions of the amino acid sequences shown in SEQ ID NOS: 1-3, which are partial sequences of the amino acid sequence composing a human CXCL1 protein; and the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognize sequence regions that differ from each other. Monoclonal antibodies or fragments thereof are provided, each of which specifically recognizes any one sequence region of the amino acid sequences shown in SEQ ID NOS: 1-3 and has a new amino acid sequence.
摘要翻译：本发明的目的是高灵敏度地检测人CXCL1蛋白。提供了人CXCL1蛋白的免疫测定方法，通过该方法，使用两种或更多种抗人CXCL1单克隆抗体或其片段测量样品中的人CXCL1或其片段，其中：所述两种或更多种类型的抗人CXCL1单克隆抗体或其片段特异性识别作为构成人CXCL1蛋白的氨基酸序列的部分序列的SEQ ID NO：1-3所示的氨基酸序列的任何一个序列区域; 两种以上抗人CXCL1单克隆抗体或其片段特异性识别彼此不同的序列区。提供了单克隆抗体或其片段，其各自特异性识别SEQ ID NO：1-3所示的氨基酸序列的任何一个序列区，并具有新的氨基酸序列。

67. 发明申请

US20160018418A1 HMGB1 AND ANTI-HMGB1 ANTIBODIES FOR THE PROGNOSTIC OF NEUROLOGICAL DISORDERS 有权
公开(公告)号：US20160018418A1
公开(公告)日：2016-01-21
申请号：US14851008
申请日：2015-09-11
申请人： INSTITUT PASTEUR
发明人： Marie-Lise Gougeon , Beatrice Poirier-Beaudoin , Valerie Seffer , Hela Saidi
IPC分类号： G01N33/68 , A61B5/055 , A61B5/15 , A61B5/00
CPC分类号： G01N33/6896 , A61B5/0042 , A61B5/055 , A61B5/15 , A61B5/4029 , A61B5/4064 , A61B5/407 , A61B5/4082 , A61B5/4088 , A61B2010/0077 , G01N33/56988 , G01N33/6854 , G01N2333/16 , G01N2333/52 , G01N2333/522 , G01N2333/523 , G01N2800/28 , G01N2800/56
摘要： The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and/or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and/or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

68. 发明申请

US20150247848A1 MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS 审中-公开
标题翻译：用于诊断和治疗川崎病和KLS的材料和方法
公开(公告)号：US20150247848A1
公开(公告)日：2015-09-03
申请号：US14427576
申请日：2013-09-12
申请人： Indiana University Research & Technology Corporation
发明人： Raymond M. Johnson
IPC分类号： G01N33/564 , C07K16/28 , C07K16/24
CPC分类号： G01N33/564 , C07K16/24 , C07K16/2866 , C07K2317/76 , G01N33/6863 , G01N2333/522 , G01N2333/523 , G01N2333/5412 , G01N2333/5437 , G01N2333/7151
摘要： Two patients diagnosed with KLS were treated. One patient had severe KLS that progressed to the equivalent of pediatric Kawasaki Disease Shock E Syndrome (KDSS). The second patient had a typical KLS presentation and clinical course. Cytokines and chemokines provide inflammatory signatures in the serum that reflect the polarity of the immune response and the affected cell types. Multiplex ELISA technology was used to define the cytokine milieu in the serum of the two adult IIIV patients with KLS during the acute and convalescent phases. Those sera were compared with sera from asymptomatic HIV subjects and a normal serum control. Those comparisons suggest that HIV KLS is a dysfunctional Th2 response to an unknown inciting agent in the vascular wall, and that a multiplex ELISA or similar technology based a limited combination of KLS/KD pathogenesis-related cytokines (IL-6, IL-13, sTNFRII) and endothelial/smooth muscle chemokines (CCL1, CCL2, CxCL11 may provide an objective tool for diagnosing KLS and Kawasaki Disease. Because KD and HIV KLS are the only known “Th2” vasculitidies that spare the lungs (unique clinical presentation) and include plasma cell infiltration of the vascular wall as a prominent histopathologic feature (unique pathophysiology), a diagnostic test based on combinations of the above analytes will be highly specific and therefore clinically useful.
摘要翻译：两名诊断为KLS的患者接受治疗。一名患者严重的KLS进展到相当于小儿川崎病震颤综合征（KDSS）。第二名患者具有典型的KLS介绍和临床课程。细胞因子和趋化因子在血清中提供反映免疫反应极性和受影响细胞类型的炎症特征。复发ELISA技术用于定义急性期和恢复期两组成人IIIV患者血清中的细胞因子环境。将这些血清与来自无症状HIV受试者的血清和正常血清对照进行比较。这些比较表明，HIV KLS是对血管壁中未知煽动剂的功能障碍Th2应答，并且基于KLS / KD发病相关细胞因子（IL-6，IL-13， sTNFRII）和内皮/平滑肌趋化因子（CCL1，CCL2，CxCL11）可以为诊断KLS和川崎病提供客观的工具，因为KD和HIV KLS是唯一已知的“Th2”血管弹药（独特的临床表现），包括作为突出的组织病理学特征（独特的病理生理学）的血管壁浆细胞浸润，基于上述分析物的组合的诊断测试将是高度特异性的，因此在临床上是有用的。

69. 发明申请

US20150125863A1 CXCL5 AS A MARKER OF HORMONE ESCAPE IN PROSTATE CANCER 审中-公开
标题翻译： CXCL5作为前列腺癌中的雄激素标记物
公开(公告)号：US20150125863A1
公开(公告)日：2015-05-07
申请号：US14596659
申请日：2015-01-14
申请人： Institut National de la Sante Recherche Medicale (INSERM)
发明人： Gwendal LAZENNEC , David VINDRIEUX , Brigitte MADLY
IPC分类号： G01N33/574 , C12Q1/68
CPC分类号： G01N33/57434 , C12Q1/6886 , C12Q2600/158 , G01N33/6863 , G01N2333/521 , G01N2333/522 , G01N2800/52
摘要： The invention relates to the use of CXCL5 as a marker for assessing hormone escape in prostate cancer cells. The invention further provides diagnostic methods and kits for assessing hormone escape in prostate cancer cells, and CXCL5 antagonists for use in the treatment or prevention of prostate cancer and/or hormone escape in prostate cancer.
摘要翻译：本发明涉及CXCL5作为评估前列腺癌细胞激素逃逸的标记物的用途。本发明还提供了用于评估前列腺癌细胞中的激素逃逸的诊断方法和试剂盒，以及用于治疗或预防前列腺癌和/或前列腺癌中的激素逃逸的CXCL5拮抗剂。

70. 发明授权

US09017958B2 Method of simultaneous detection of heparin-induced immunoglobulins types G, A, and M 有权
标题翻译：同时检测肝素诱导的G，A，M型免疫球蛋白的方法
公开(公告)号：US09017958B2
公开(公告)日：2015-04-28
申请号：US14193391
申请日：2014-02-28
申请人： Blood Center Research Foundation
发明人： Brian R. Curtis
IPC分类号： G01N33/00 , G01N33/68 , G01N33/86
CPC分类号： G01N33/6854 , G01N33/86 , G01N2333/522 , G01N2333/745 , G01N2400/40 , G01N2800/222
摘要： The invention provides a method for detecting heparin-induced antibodies comprising a) binding a PF4-heparin antigen to a solid surface; b) incubating the bound PF4-heparin with a sample comprising heparin-induced antibodies to be detected; c) contacting the sample with at least two labeled secondary antibodies, wherein the secondary antibodies bind to heparin-induced antibodies present in the sample; d) detecting the presence of the labeled secondary antibodies using flow cytometry or a suitable method, wherein the heparin-induced antibodies bound to the secondary antibodies are identified. In one embodiment, the at least two secondary antibodies are anti-human antibodies which specifically bind to heparin-induced antibodies and are selected from the group consisting of Ig, IgG, IgA, and IgM.
摘要翻译：本发明提供了检测肝素诱导的抗体的方法，其包括：a）将PF4-肝素抗原结合到固体表面; b）将结合的PF4-肝素与包含待检测的肝素诱导的抗体的样品孵育; c）使所述样品与至少两种标记的二抗接触，其中所述第二抗体结合存在于所述样品中的肝素诱导的抗体; d）使用流式细胞术或合适的方法检测标记的第二抗体的存在，其中鉴定与第二抗体结合的肝素诱导的抗体。在一个实施方案中，所述至少两种第二抗体是特异性结合肝素诱导的抗体并且选自Ig，IgG，IgA和IgM的抗人抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式